Target & Biomarker Discovery Service

About Aignostics

Aignostics is a Berlin-based, Charité spin-off founded in 2018, operating at the intersection of AI, digital pathology, and oncology. The company has developed a robust platform centered on proprietary pathology foundation models, which power its products (like the Atlas H&E-TME application) and custom services for biopharma partners. With access to multimodal data from over 30 million patients, deep collaborations with academic institutions like Mayo Clinic, and key industry partnerships (e.g., Bayer), Aignostics is positioned as a leading AI enabler for precision medicine in pathology and drug development. It is a private, likely revenue-generating company providing a mix of platform technology and bespoke analytical services.

Therapeutic Areas